I agree that this site is using cookies. You can find further informations here.
X
Woyach, J.
312  results:
Search for persons X
?
1

Long‐term safety with ≥12 months of pirtobrutinib in relaps..:

Wang, Y. ; Coombs, C. C. ; Shah, N. N....
Hematological Oncology.  41 (2023)  S2 - p. 480-481 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Updated follow‐up of BELLWAVE‐001: an open‐label, single‐ar..:

Eradat, H. ; Woyach, J. ; Flinn, I. W....
Hematological Oncology.  41 (2023)  S2 - p. 565-567 , 2023
Link: https://doi.org/10.1002/..
 
?
3

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Patel, K. ; Brown, J. R. ; Desikan, S. P....
Hematological Oncology.  41 (2023)  S2 - p. 185-187 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 249-250 , 2023
Link: https://doi.org/10.1002/..
 
?
5

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STU..:

Mato, A. R. ; Wierda, W. G. ; Pagel, J. M....
HemaSphere.  6 (2022)  - p. 1743-1744 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere.  6 (2022)  - p. 991-992 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF ..:

Woyach, J. ; Flinn, I. W. ; Awan, F. T....
HemaSphere.  6 (2022)  - p. 578-579 , 2022
Link: https://doi.org/10.1097/..
 
?
8

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 48-49 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P655: RACIAL AND SOCIOECONOMIC DISPARITIES AMONG PATIENTS W..:

Kittai, A. ; Huang, Y. ; Fisher, J....
HemaSphere.  6 (2022)  - p. 553-554 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN..:

Davids, M. ; Sharman, J. ; Ghia, P....
HemaSphere.  6 (2022)  - p. 565-566 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORA..:

Sharman, J. P. ; Egyed, M. ; Jurczak, W....
HemaSphere.  6 (2022)  - p. 564-565 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELEC..:

Frigault, M. ; Sher, S. ; Ravikrishnan, J....
HemaSphere.  6 (2022)  - p. 1154-1155 , 2022
Link: https://doi.org/10.1097/..
 
?
13

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIV..:

Jurczak, W. ; Shah, N. N. ; Lamanna, N....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
14

The Relationship of Relative Dose Intensity with Chemothera..:

Rosko, A. ; Huang, Y. ; Funderburg, A....
Journal of Geriatric Oncology.  12 (2021)  8 - p. S17 , 2021
Link: https://doi.org/10.1016/..
 
?
15

CN4 Patient-Reported Outcomes from the Phase 3, Randomized ..:

Walker, P. ; Sharman, J.P. ; Jurczak, W....
Value in Health.  24 (2021)  - p. S3-S4 , 2021
Link: https://doi.org/10.1016/..
 
1-15